4053 research outputs found
Sort by
Prognostic role of ABO blood group and Rhesus factor in cirrhotic patients with hepatocellular carcinoma
No full textOral, Alihan/0000-0003-1160-9340WOS: 000503165500001PubMed: 31836844Hepatocellular carcinoma (HCC) is one of the most common types of cancer worldwide. There are many factors in the etiology of HCC such as hepatitis B virus (HBV), hepatitis C virus (HCV), alcohol, obesity, smoking and aflatoxin. Many types of cancer are assumed to be associated with ABO blood group and Rhesus factor (RH). in this study we aimed to evaluate the relationship between tumor characteristics and overall survival (OS), ABO blood group and RH factor in patients with HCC. A total of 507 patients with chronic liver disease (252 patients with HCC and 255 patients without HCC) were included in the study. All demographic, clinic and laboratory (biochemical parameters and blood type) features were collected retrospectively. the mean age of the patients was 54.50 +/- 9.30. There was no significant difference in both ABO groups and RH factors between the two groups. We found that vascular invasion rate of the tumor was higher in the B blood group and multicentric localization of tumor was significantly higer in patients with positive RH but there was no difference between OS in ABO and RH blood groups. in addition, the tumor was less multicentric in the AB blood group. Blood groups and RH factor can be used to predict the prognosis in cirrhotic patients with HCC
Changes in the expression levels of CB1 and GLP-1R mRNAs and microRNAs 33a and 122 in the liver of type 2 diabetic rats treated with ghrelin
No full textcoskun, zeynep mine/0000-0003-4791-6537; Bolkent, Sema/0000-0001-8463-5561WOS: 000484212400001PubMed: 31468622The aim of the study is to clarify the effect of ghrelin treatment on the messenger RNA (mRNA) expression of the cannabinoid receptor 1 (Cnr1/CB1) and glucagon-like peptide 1 receptor (Glp1r/GLP-1R) as well as microRNAs (miR)-122 and miR-33a in the liver of rats with type 2 diabetes mellitus (T2DM). Adult Sprague-Dawley rats were divided into three groups: control (n = 7), T2DM (n = 7), and treatment (n = 7). Control animals received tap water. T2DM was induced by feeding 10% fructose in drinking water for 2 weeks followed by a single injection of streptozotocin (40 mg/kg, intraperitoneally [IP]). in the treatment group, diabetic rats were injected ghrelin (25 mu g/kg, IP) for 14 days. Serum lipid profiles were evaluated, and mRNA expression levels of Cnr1 and Glp1r in the liver were detected using quantitative real-time polymerase chain reaction (RT-qPCR). in addition, miR-122 and miR-33a levels were measured using RT-qPCR. Serum triglycerides, low-density lipoprotein cholesterol, and very-low-density lipoprotein cholesterol significantly increased in the T2DM group compared with control rats but ghrelin treatment showed no effect on serum lipid levels. the mRNA expression levels of Cnr1 and Glp1r decreased in the T2DM group compared with the control group. These reductions were significantly increased in the T2DM group treated with ghrelin. Furthermore, the increase in miR-33a expression level was reduced in the treatment group compared to rats with T2DM. Our findings suggested that ghrelin treatment may alter the mRNA expression levels of CB1 and GLP-1R in the liver of rats with T2DM. the mRNA levels of Cnr1 and Glp1r may inversely correlate with the expression level of miR-33a but not miR-122
Real world efficacy and safety of teriflunomide in multiple sclerosis: an observational study with four years follow-up
No full text35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS -- SEP 11-13, 2019 -- Stockholm, SWEDENTurkoglu, Recai/0000-0001-9724-851X; Yetkin, Mehmet Fatih/0000-0002-2541-7107; Boz, Cavit/0000-0003-0956-3304WOS: 000485303103364[No abstract available]European Comm Treatment & Res Multiple Sclerosis, Congrex Switzerland Lt
Diagnostic performance of MRI texture features in prediction of microvascular invasion in HCCs of pre-transplant patients
No full text25th Annual International Congress of the International-Liver-Transplantation-Society (ILTS) -- MAY 15-18, 2019 -- Toronto, CANADAWOS: 000494805000809[No abstract available]Int Liver Transplantat So
Hippocampal apoptosis, neurogenesis suppression, BDNF, TrkB, CREB expression in depressed female and male rats
No full text32nd Congress of the European-College-of-Neuropsychopharmacology (ECNP) -- SEP 07-10, 2019 -- Copenhagen, DENMARKWOS: 000502657504088[No abstract available]European Coll NeuropsychopharmacolErciyes University Research FundErciyes University [TOA-2015-5368]This study was supported by the Erciyes University Research Fund (TOA-2015-5368)
Do we need patent native IVC for LDLT? Transdiaphragmatic dacron graft replacement leaving native thrombosed IVC in LDLT, surgical video presentation
No full text25th Annual International Congress of the International-Liver-Transplantation-Society (ILTS) -- MAY 15-18, 2019 -- Toronto, CANADAWOS: 000494805000869[No abstract available]Int Liver Transplantat So
Acute Kidney Injury After Pediatric Liver Transplantation
No full text1st International Transplant Network Congress -- OCT 17-21, 2018 -- Antalya, TURKEYFERAH, OYA/0000-0001-5585-7368;WOS: 000487349900080PubMed: 31443924Background. the aim of the present study is to assess acute kidney injury (AKI) incidence according to the pRIFLE and AKIN criteria and to evaluate the risk factors for early developing AKI in postoperative intensive care unit after pediatric liver transplantation (LT). Materials. After exclusion of retransplantations, 7 cadaveric and 44 living donors, totaling 51 pediatric LT patients that were performed between 2005 and 2017, were reviewed retrospectively. AKI was defined according to both pediatric RIFLE (Risk for renal dysfunction, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal disease) and Acute Kidney Injury Network (AKIN) criteria. Documented data were compared between AKI and non-AKI patients. Results. AKI incidences were 17.6% by AKIN and 37.8% by pRIFLE criteria. AKIN-defined AKI group had statistically lower serum albumin level, higher serum sodium level, higher furosemide dose, and higher rate of red blood cell (RBC) transfusion than the non-AKI group (P = .02, P = .02, P = .01 and P = .04, respectively). AKI patients had significantly prolonged mechanical ventilation (P = .01) and hospital LOS (P = .02). the pRIFLE-defined AKI group had significantly lower serum albumin level, higher blood urea nitrogen (BUN) level, and higher ascites drained and also showed higher requirement for RBC and 20% human albumin transfusions than the non-AKI group (P = .02, P = .04, P: =.007, P = .02 and P = .05, respectively). Conclusion. We evaluated that hypoalbuminemia, high requirement for RBC and 20% human albumin transfusions, high serum sodium, high furosemide use, and high flow of ascites are risk factors for AKI and high BUN levels can be predictive for AKI in pediatric LT patients. the effect of AKI on outcome variables were prolonged mechanical ventilation and hospital LOS
Intrinsic functional connectivity in social anxiety disorder with and without comorbid attention deficit hyperactivity disorder
No full textTukel, Rasit/0000-0001-9421-4541; KURT, ELIF/0000-0003-1956-575X; Demiralp, Tamer/0000-0002-6803-734X; Ulasoglu-Yildiz, Cigdem/0000-0003-1849-0055WOS: 000491301400022PubMed: 31400309Neuroimaging research about social anxiety disorder (SAD) points to hyperactivity in the fear circuit and altered connectivity between the fear circuit and the intrinsic connectivity networks that modulate it. We investigated intrinsic functional connectivity changes in SAD patients by taking into consideration the commonly overlooked comorbidity of attention deficit hyperactivity disorder (ADHD). We compared intrinsic functional connectivity alterations in 16 patients with pure SAD, 18 patients with SAD and comorbid ADHD and 21 healthy controls using seed-to-voxel functional connectivity analyses. Hypoconnectivity of the right fusiform gyms with the left lingual gyrus was the unique difference between whole SAD group and healthy controls, while in the pure SAD group the fusiform gyrus displayed hypoconnectivity with the posterior default mode network (DMN) regions. in contrast, ADHD comorbidity was associated with hyperconnectivities of the salience network (SN) with the fusiform cortex and the posterior DMN regions, and hyperconnectivities of the posterior DMN with visual, somatosensory and motor cortices. the dichotomic dissociation of the SAD related functional connectivity changes into hypoconnectivities in the pure SAD group vs hyperconnectivities in the SAD-ADHD group leads also to the question, whether ADHD treatment can be considered an alternative for selected SAD cases.Istanbul University Scientific Research Projects UnitIstanbul University [2805/52065, 1567/42362]This study was supported by Istanbul University Scientific Research Projects Unit (Projects ID/number: 2805/52065 and 1567/42362)
A rare cause of acute coronary syndromes in young adults - myeloproliferative neoplasms: A case series
No full textWOS: 000503202800001PubMed: 31784298Introduction: Acute coronary syndromes (ACS) mostly occur in patients with traditional risk factors. Especially in young adults without major cardiovascular (CV) risk factors, one of the less common causes of ACS is myeloproliferative neoplasms (MPNs). Methods: We retrospectively collected data on 11 consecutive patients (nine men, two women, mean age 40.18 +/- 8.4 years) with a diagnosis of MPN who presented with ACS. the demographic characteristics of the study population, type of MPN, clinical manifestations, location of myocardial infarction (MI), coronary angiography findings, complete blood count and other related findings, and treatment strategy before and after diagnosis were analyzed. Results: Six patients were diagnosed with polycythemia vera, four with essential thrombocytosis and one with primary myelofibrosis. A JAK2 mutation was found in nine patients. Mean time to diagnosis of MPN was 2.81 years after presenting ACS and mean age at first MI was 32.9 +/- 6 years. Six patients had no major CV risk factors. Ten patients had anterior MI and one had inferior MI. After initiation of specific treatment for MPN, no recurrent thrombotic events were observed in a mean follow-up of 4 +/- 2.44 years. Conclusions: in young adults presenting with ACS, MPNs should be considered, especially in the absence of atherosclerotic coronary artery lesions. It is also important to pay attention to blood cell count abnormalities seen in intracoronary thrombotic events. Early diagnosis and treatment of MPNs is essential to prevent recurrence of thrombotic events and may reduce mortality and morbidity related to thrombotic complications. (C) 2019 Sociedade Portuguesa de Cardiologia. Published by Elsevier Espana, S.L.U
Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis
No full textBoz, Cavit/0000-0003-0956-3304; Altintas, Ayse/0000-0002-8524-5087; YUCEYAR, NUR/0000-0003-4590-6423; Sevim, Serhan/0000-0002-0518-3374; Efendi, Husnu/0000-0002-9143-3893WOS: 000502098900008PubMed: 31473488Background: Fingolimod and teriflunomide are commonly used in the treatment of relapsing-remitting multiple sclerosis (RRMS). These have not been compared in controlled trials, but only in observational studies, with inconclusive results. Comparison of their effect on relapse and disability in a real-world setting is therefore needed. Objectives: the objective of this study was to compare the efficacy of fingolimod and teriflunomide in reducing disease activity in RRMS. Methods: This multicenter, retrospective observational study was carried out with prospectively collected data from 15 centers. All consecutive RRMS patients treated with teriflunomide or fingolimod were included. Data for relapses, Expanded Disability Status Scale (EDSS) scores and brain magnetic resonance imaging (MRI) scans were collected. Patients were matched using propensity scores. Annualized relapse rates (ARR), disability accumulation, percentage of patients with active MRI and treatment discontinuation over a median 2.5-year follow-up period were compared. Results: Propensity score matching retained 349 out of 1388 patients in the fingolimod group and 349 out 678 in the teriflunomide group for final analyses. Mean ARR decreased markedly from baseline after 1 and 2 years of treatment in both the fingolimod (0.58-0.17 after 1 year and 0.11 after 2 years, p < 0.001) and teriflunomide (0.56-0.29 after 1 year and 0.31 after 2 years, p < 0.001) groups. Mean ARR was lower in fingolimod-treated patients than in those treated with teriflunomide at years 1 (p = 0.02) and 2 (p = 0.004). Compared to teriflunomide, the fingolimod group exhibited a higher percentage of relapse-free patients and a lower percentage of MRI-active patients after 2.5-year follow-up. Disability worsening was similar between the two groups. Patients were less likely to discontinue fingolimod than teriflunomide (p < 0.001). Conclusion: Fingolimod was associated with a better relapse control and lower discontinuation rate than teriflunomide. the two oral therapies exhibited similar effects on disability outcomes